1. Home
  2. PRG vs NTLA Comparison

PRG vs NTLA Comparison

Compare PRG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRG
  • NTLA
  • Stock Information
  • Founded
  • PRG 2020
  • NTLA 2014
  • Country
  • PRG United States
  • NTLA United States
  • Employees
  • PRG N/A
  • NTLA N/A
  • Industry
  • PRG Diversified Commercial Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • PRG Consumer Discretionary
  • NTLA Health Care
  • Exchange
  • PRG Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • PRG 2.0B
  • NTLA 1.4B
  • IPO Year
  • PRG N/A
  • NTLA 2016
  • Fundamental
  • Price
  • PRG $49.65
  • NTLA $16.06
  • Analyst Decision
  • PRG Strong Buy
  • NTLA Buy
  • Analyst Count
  • PRG 6
  • NTLA 17
  • Target Price
  • PRG $52.60
  • NTLA $58.63
  • AVG Volume (30 Days)
  • PRG 314.6K
  • NTLA 2.8M
  • Earning Date
  • PRG 10-23-2024
  • NTLA 11-07-2024
  • Dividend Yield
  • PRG 0.97%
  • NTLA N/A
  • EPS Growth
  • PRG 8.67
  • NTLA N/A
  • EPS
  • PRG 3.58
  • NTLA N/A
  • Revenue
  • PRG $2,417,577,000.00
  • NTLA $45,967,000.00
  • Revenue This Year
  • PRG $2.94
  • NTLA $49.33
  • Revenue Next Year
  • PRG $6.29
  • NTLA $9.99
  • P/E Ratio
  • PRG $12.76
  • NTLA N/A
  • Revenue Growth
  • PRG N/A
  • NTLA N/A
  • 52 Week Low
  • PRG $26.39
  • NTLA $13.95
  • 52 Week High
  • PRG $50.28
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • PRG 64.55
  • NTLA 40.65
  • Support Level
  • PRG $43.66
  • NTLA $14.55
  • Resistance Level
  • PRG $44.80
  • NTLA $16.98
  • Average True Range (ATR)
  • PRG 1.50
  • NTLA 1.01
  • MACD
  • PRG 0.32
  • NTLA -0.14
  • Stochastic Oscillator
  • PRG 99.06
  • NTLA 28.06

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The Company has two reportable segments: (i) Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and (ii) Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the progressive leasing segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: